Research Article
Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure
Table 1
Baseline characteristics of the study participants.
| | | DCM
()
mean SEM OR
(%) | ICM
()
mean SEM OR
(%) | HCM
()
mean SEM OR
(%) | value |
| | Age in years | 55 12 | 60 8 | 62 14 | n.s. | | Male | 9 (81) | 11 (92) | 7 (70) | n.s. | | BMI in kg/m2 | 31 2.9 | 29 5.7 | 33 5.6 | n.s. | | Cardiovascular risk factors | | | | | | Hypertension | 6 (54) | 9 (75) | 11 (100) | <0.001 | | Diabetes mellitus | 5 (45) | 8 (66) | 4 (40) | n.s. | | Smoking | 3 (27) | 8 (66) | 1 (10) | n.s. | | Dyslipidaemia | 5 (45) | 8 (66) | 6 (60) | n.s. | | Obesity (BMI > 30 kg/m2) | 8 (73) | 7 (58) | 6 (60) | n.s. | | Medication | | | | | | Beta blockers | 11 (100) | 12 (100) | 10 (100) | n.s. | | ACE-inhibitors/ARB | 11 (100) | 12 (100) | 10 (100) | n.s. | | Aldosterone antagonists | 7 (64) | 8 (66) | 6 (60) | n.s. | | Clinical Presentation | | | | | | Angina pectoris | 0 (0) | 1 (8) | 1 (10) | n.s. | | NYHA class | 2.2 0.6 | 2.2 0.9 | 2.4 1.0 | n.s. | | Peripheral oedema | 1 (9) | 3 (25) | 3 (30) | n.s. | | Heart rate | 80 8.1 | 80 4.8 | 80 7.4 | n.s. | | RR sys | 123 16 | 148 21 | 149 26 | n.s. | | RR dia | 82 12 | 88 11 | 87 11 | n.s. | | Floors | 2.4 1.2 | 2.3 1.1 | 2.4 1.9 | n.s. | | Echocardiography | | | | | | LV-EF in % | 31 8 | 35 8 | 33 12 | n.s. | | LVEDd in mm | 61 8 | 59 11 | 66 11 | n.s. | | PAPsys in mmHg (excl. CVP) | 24 6 | 19 9 | 21 2 | n.s. |
|
|
ARB: aldosterone-receptor blocker, BMI: body mass index, CVP: central venous pressure, DCM: dilated cardiomyopathy, HCM: hypertensive cardiomyopathy, ICM: ischemic cardiomyopathy, LVEDd: left ventricular end-diastolic diameter, LV-EF: left ventricular ejection fraction, NYHA: New York Heart Association, and PAPsys: systolic pulmonary artery pressure.
|
